DocMorris AG Finalizes AGM Agenda and Capital Increase Plans

DocMorris AG has unveiled the final details for its Annual General Meeting and a planned capital increase. The company announced conditions for a fully underwritten capital increase, expected to raise CHF 200 million. This initiative aims to boost the prescription medicine segment and potentially repay a CHF 95 million convertible bond due in September 2026.

The board proposed several capital measures, including an ordinary capital increase to CHF 510,178.83 through issuing 36,182,790 new shares. Existing shareholders will receive three new shares for one subscription right, with rights trading on the SIX Swiss Exchange from May 13 to May 19, 2025.

DocMorris reported a 13.4% rise in external revenue to CHF 296.5 million in Q1 2025, despite an EBITDA loss of CHF 16.2 million due to increased marketing expenditures. The company confirmed its revenue and earnings forecasts for 2025, supported by ongoing growth in the Rx business and TeleClinic.